![]() Provides an overview of the available literature on the changes observed internationally following the implementation of childhood PNEU-C programs on the general population of adults.Provides an update to the review of the literature on the use of PNEU-P-23 in adults.Updates the epidemiology of pneumococcal disease in those 65 years of age and older in Canada with regards to serotypes included in PNEU-P-23 and PNEU-C-13 using the most recently available national surveillance data (2015) The objective of this Statement Update is to provide evidence and recommendations, from a public health perspective, for the use of pneumococcal vaccines for the prevention of community-acquired pneumonia (CAP) and invasive pneumococcal disease (IPD) in adults 65 years of age and older, without other risk factors increasing their risk of IPD. Although there is clinical trial evidence for PNEU-C-13 vaccine efficacy in older adults for preventing IPD and CAP, currently within the Canadian context, such a publicly funded program would not significantly decrease the disease burden in a cost-effective manner. pneumoniae serotypes causing IPD and CAP in Canada and the evidence of changing incidence of pneumococcal disease following the implementation of childhood PNEU C vaccination programs. The programmatic recommendation for adults age 65 years and older is based on the epidemiology of circulating S. Individual-level recommendations for PNEU-C-13 vaccine have been discussed in the 2016 NACI recommendations. One dose of PNEU-P-23 vaccine is recommended for all adults 65 years of age and older, regardless of risk factors or previous pneumococcal vaccination. Howįor routine, publicly funded, immunization programs for adults 65 years of age without other risk factors increasing their risk of IPD, NACI does not recommend the inclusion of PNEU-C-13 vaccine at its current price. These recommendations supplement the recent NACI recommendations on this topic that were issued for individual-level decision making in 2016. Information in this statement is intended for provinces and territories (P/Ts) making decisions for publicly funded, routine, immunization programs for adults who are 65 years of age and older without risk factors increasing their risk of IPD. NACI members and liaison members conduct themselves within the context of PHAC's Policy on Conflict of Interest, including yearly declaration of potential conflict of interest. Manufacturer(s) have sought approval of the vaccine(s) and provided evidence as to its safety and efficacy only when it is used in accordance with the product monographs. Recommendations for use and other information set out herein may differ from that set out in the product monograph(s) of the Canadian manufacturer(s) of the vaccine(s). People administering the vaccine should also be aware of the contents of the relevant product monograph(s). PHAC acknowledges that the advice and recommendations set out in this statement are based upon the best current available scientific knowledge and is disseminating this document for information purposes. The National Advisory Committee on Immunization (NACI) provides the Public Health Agency of Canada (hereafter referred to as the PHAC) with ongoing and timely medical, scientific, and public health advice relating to immunization.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |